Physician profile
Brian A Hickey
NPI 1700968518
$8,265.57
in general payments reported to CMS, 2019-2025
22 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 93% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,722 · 2022: $1,427 · 2023: $1,941 · 2024: $1,768 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,116.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,004.49 | 2021-2025 | |
| Alkermes, INC. | $901.28 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $860.58 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $597.83 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Vanda Pharmaceuticals INC. | $584.71 | 2021-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $340.51 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $322.55 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $300.03 | 2021-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $289.53 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $230.94 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $144.86 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $144.45 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $138.73 | 2021-2022 | |
| Neos Therapeutics, Lp | $80.76 | 2021-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $64.81 | 2022-2025 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.15 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $45.44 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $43.51 | 2021-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $39.62 | 2023 | Quviviq |
| Bausch Health US, LLC | $29.12 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.34 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.33 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.